United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond Sells 7,792 Shares

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,792 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $358.62, for a total transaction of $2,794,367.04. Following the transaction, the chief financial officer now owns 4,802 shares in the company, valued at $1,722,093.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The stock was sold at an average price of $354.04, for a total transaction of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $357.83 on Wednesday. The stock has a market capitalization of $15.87 billion, a price-to-earnings ratio of 16.92, a price-to-earnings-growth ratio of 1.30 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The business has a 50-day moving average of $343.01 and a 200 day moving average of $297.78. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same period in the previous year, the business posted $5.24 EPS. The company’s revenue for the quarter was up 19.8% compared to the same quarter last year. As a group, sell-side analysts forecast that United Therapeutics Co. will post 24.71 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently modified their holdings of the business. LSV Asset Management boosted its holdings in United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the period. Swedbank AB purchased a new position in shares of United Therapeutics in the 1st quarter valued at about $97,316,000. Nordea Investment Management AB grew its position in shares of United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after buying an additional 262,222 shares in the last quarter. Avidity Partners Management LP purchased a new stake in shares of United Therapeutics during the fourth quarter worth approximately $52,158,000. Finally, Canada Pension Plan Investment Board raised its holdings in United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after acquiring an additional 153,700 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. UBS Group boosted their price objective on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Jefferies Financial Group boosted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. HC Wainwright restated a “buy” rating and set a $400.00 price target on shares of United Therapeutics in a report on Thursday, August 1st. Oppenheimer upped their price objective on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a report on Wednesday, August 28th. Finally, Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $357.17.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.